PharmAla Biotech Holdings Inc. announced that it had entered into a binding sales agreement with Numinus Wellness Inc. to provide its GMP LaNeo? MDMA for a prospective clinical trial.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.19 CAD | -7.32% | 0.00% | +35.71% |
May. 03 | PharmAla Up Near 8% As Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy | MT |
Apr. 23 | Red Light Holland Corp. Initiates Psilocybin Extraction Phase with PharmAla | CI |
1st Jan change | Capi. | |
---|---|---|
+35.71% | 12.98M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- MDMA Stock
- News Pharmala Biotech Holdings Inc.
- Pharmala Biotech Holdings Inc. Signs Sale Agreement with Numinus